Nanoviricides (NNVC) Trading Update – 21 Oct 2026
Market Performance
| Item | Value |
|---|---|
| Closing price (10:14 PM CET, Wednesday 21 Oct 2026) | $1.51 |
| 24‑hour change | +13.85 % |
| Shares outstanding | 25.5 million |
| Market capitalization | $33.2 million |
| 24‑hour trading volume | $686 k |
| 12‑month change (since last month’s close) | ‑12.43 % |
| 200‑day simple moving average | $1.28 |
| 52‑week high | $2.23 (05 Nov 2025) |
| 52‑week low | $0.85 (02 May 2026) |
Nanoviricides’ shares increased significantly during the trading session, closing at $1.51, up 13.85 % from the previous close. The 200‑day moving average at $1.28 indicates a bullish trend relative to its recent average price.
Related Stock Activity (24‑hour period)
| Ticker | Company | 24‑hour change | Current price | Market cap | Notes |
|---|---|---|---|---|---|
| CNSY | Cerenome | +22.45 % | $1.70 | $39.3 million | N/A |
| PRPO | Precipio | ‑0.78 % | $21.04 | $39.2 million | Two Form 4 filings on 19 Oct 2026 detail board‑member share awards. Cohen S. David received 582 shares; Christina Rizopoulos received 122 shares, increasing holdings to 55 781 and 5 750 shares respectively. |
| GRCE | Grace Therapeutics | +5.32 % | $1.97 | $39.6 million | N/A |
| TIL | Instil Bio | +2.59 % | $5.77 | $39.3 million | N/A |
| VERU | Veru | +3.03 % | $2.30 | $39.4 million | Analysts note modest uptick in investor confidence, citing positive sentiment around strategic initiatives and earnings guidance that aligns with long‑term growth targets. |
Company Background
Nanoviricides, Inc. is a biopharmaceutical company headquartered in West Haven, United States. The company focuses on developing antiviral therapies for diseases including HIV/AIDS, hepatitis C, influenza, and avian influenza. Nanoviricides is listed on the NYSE MKT exchange and maintains its corporate website at www.nanoviricides.com .